172 related articles for article (PubMed ID: 10174323)
1. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine.
Evans KW; Boan JA; Evans JL; Shuaib A
Pharmacoeconomics; 1997 Nov; 12(5):565-77. PubMed ID: 10174323
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
Zhang L; Hay JW
CNS Drugs; 2005; 19(7):635-42. PubMed ID: 15984898
[TBL] [Abstract][Full Text] [Related]
3. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
McCormack PL; Foster RH
Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine.
Lofland JH; Kim SS; Batenhorst AS; Johnson NE; Chatterton ML; Cady RK; Kaniecki R; Nash DB
Mayo Clin Proc; 2001 Nov; 76(11):1093-101. PubMed ID: 11702897
[TBL] [Abstract][Full Text] [Related]
5. [Almotriptan vs. ergotamine plus caffeine for acute migraine treatment. A cost-efficacy analysis].
Slof J; Láinez JM; Comas A; Heras J
Neurologia; 2009 Apr; 24(3):147-53. PubMed ID: 19418289
[TBL] [Abstract][Full Text] [Related]
6. [Sumatriptan in the treatment of acute migraine: its role in primary health care].
Anaya Ordóñez S; Matas Hoces A
Aten Primaria; 1994 Apr; 13(7):387-90. PubMed ID: 8003603
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison.
Asseburg C; Peura P; Oksanen T; Turunen J; Purmonen T; Martikainen J
Int J Technol Assess Health Care; 2012 Oct; 28(4):382-9. PubMed ID: 23013610
[TBL] [Abstract][Full Text] [Related]
8. Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997.
Rahimtoola H; Egberts AC; Buurma H; Tijssen CC; Leufkens HG
Cephalalgia; 2001 Jun; 21(5):596-603. PubMed ID: 11472386
[TBL] [Abstract][Full Text] [Related]
9. Reduction in the intensity of abortive migraine drug use during coumarin therapy.
Rahimtoola H; Egberts AC; Buurma H; Tijssen CC; Leufkens HG
Headache; 2001 Sep; 41(8):768-73. PubMed ID: 11576200
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation.
Laloux P; Vakaet A; Monseu G; Jacquy J; Bourgeois P; van der Linden C
Acta Neurol Belg; 1998 Dec; 98(4):332-41. PubMed ID: 9922821
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.
Eur Neurol; 1991; 31(5):314-22. PubMed ID: 1653139
[TBL] [Abstract][Full Text] [Related]
12. Sumatriptan. An updated review of its use in migraine.
Perry CM; Markham A
Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601
[TBL] [Abstract][Full Text] [Related]
13. An economic evaluation of rizatriptan in the treatment of migraine.
Thompson M; Gawel M; Desjardins B; Ferko N; Grima D
Pharmacoeconomics; 2005; 23(8):837-50. PubMed ID: 16097844
[TBL] [Abstract][Full Text] [Related]
14. When should triptans be taken during a migraine attack?
Schoenen J
CNS Drugs; 2001; 15(8):583-7. PubMed ID: 11524030
[TBL] [Abstract][Full Text] [Related]
15. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of the acute migraine attack].
Titus F
Rev Neurol; 1995; 23 Suppl 2():S203-7. PubMed ID: 7497289
[No Abstract] [Full Text] [Related]
17. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis.
Payne K; Kozma CM; Lawrence BJ
Pharmacoeconomics; 1996 Jul; 10(1):59-71. PubMed ID: 10160470
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of sumatriptan in a managed care population.
Legg RF; Sclar DA; Nemec NL; Tarnai J; Mackowiak JI
Am J Manag Care; 1997 Jan; 3(1):117-22. PubMed ID: 10169243
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic treatment of recurrent pediatric headache.
Graf WD; Riback PS
Pediatr Ann; 1995 Sep; 24(9):477-84. PubMed ID: 8552424
[No Abstract] [Full Text] [Related]
20. HMO direct costs and health care resources use after implementation of a monthly limit on sumatriptan.
Goldfarb SD; Duncan BS; Dans PE; Sloan AS
Am J Health Syst Pharm; 1999 Nov; 56(21):2206-10. PubMed ID: 10565699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
